
The Income Tax Department has appealed to the Income Tax Appellate Tribunal (ITAT), New Delhi, against an order granting Dr Lal PathLabs relief on ₹32.66 crore in ESOP expenses for assessment year 2022-23 (income from April 2021 to March 2022). The diagnostic company disclosed the appeal in a regulatory filing on Thursday, 8 October 2026, after receiving intimation on 7 October.

The appeal challenges an order passed by the Commissioner of Income Tax (Appeals) under Section 250 of the Income Tax Act, 1961, which had ruled in the company's favour. The company said it does not expect the outcome to have any material impact on its operations. Dr Lal PathLabs shares closed at ₹1,898.90 on the NSE on 8 October, down 2.38 per cent.
Both thehindubusinessline.com and economictimes.indiatimes.com provide straight, neutral reporting of the company's regulatory filing, with no discernible slant toward or against the government. Thehindubusinessline.com adds stock price and market context, while economictimes.indiatimes.com notes the section of law and links to another company's regulatory news, but neither outlet frames the appeal as a setback for the company or as an aggressive revenue move. The uniform coverage indicates no editorial divergence on this issue. The next step is the ITAT hearing, whose timing the sources do not specify.
Coverage: 2 sources, 2 neutral
Sources (2): thehindubusinessline.com (neutral report), economictimes.indiatimes.com (neutral report)
This brief was synthesised by AI from the 2 sources linked above, so one read covers every framing they carry. Methodology and corrections.